Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbbVieMEX:ABBV 72 5-Year Yield-on-Cost % is 3.83 as of Jul. 16, 2026, which is 24% below its 10-year median of 5.01. GuruFocus rates MEX:ABBV with a GF Score™ of 72/100 and a GF Value™ of MXN3,770.50 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 514 Drug Manufacturers companies, AbbVie ranks better than 65.18% on this metric.
AbbVie's yield on cost for the quarter that ended in Mar. 2026 was 3.83.
The historical rank and industry rank for AbbVie's 5-Year Yield-on-Cost % or its related term are showing as below:
MEX:ABBV'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.86 Med: 5.01 Max: 8.67
Current: 3.83
During the past 13 years, AbbVie's highest Yield on Cost was 8.67. The lowest was 2.86. And the median was 5.01.
MEX:ABBV's 5-Year Yield-on-Cost % is ranked better than 65.18% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs MEX:ABBV: 3.83
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
AbbVie 5-Year Yield-on-Cost % Related Terms
MEX:ABBV vs MRK, JNJ, AMGN: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, AbbVie's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where AbbVie's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of AbbVie is calculated as
AbbVie (MEX:ABBV) has a 5-Year Yield-on-Cost % of 3.83 as of Jul. 16, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on AbbVie and its competitors. This is 24% below median its historical median of 5.01. Over the past decade, AbbVie's 5-Year Yield-on-Cost % has ranged from 2.86 to 8.67. According to the industry distribution chart, AbbVie ranks #179 out of 514 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is AbbVie's 5-Year Yield-on-Cost % too high?
AbbVie's current 5-Year Yield-on-Cost % of 3.83 is 24% below median its 10-year median of 5.01. Over the past 10 years, this metric has ranged from a low of 2.86 to a high of 8.67. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. AbbVie's value of 3.83 is 66.5% above this industry median. Based on the distribution chart, AbbVie ranks #179 out of 514 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AbbVie has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's 5-Year Yield-on-Cost % compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #179 out of 514 companies for 5-Year Yield-on-Cost %. This puts AbbVie in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.30. AbbVie's value of 3.83 is 66.5% above this benchmark. Historically, AbbVie's own 5-Year Yield-on-Cost % has ranged from 2.86 to 8.67 over the past decade. While the company's 10-year median is 5.01 vs. the industry median of 2.30, AbbVie has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current 5-Year Yield-on-Cost % of 3.83 is 66.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current 5-Year Yield-on-Cost % is 3.83, which is 24% below median its own 10-year median of 5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,770.50, compared to a current price of MXN4,331.99 — trading 14.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 3.83, which is 24% below median its 10-year median of 5.01 and 66.5% above the Drug Manufacturers industry median of 2.30. AbbVie's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current 5-Year Yield-on-Cost % is 3.83 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (MEX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of MXN4,331.99 is trading 14.9% above its estimated GF Value™ of MXN3,770.50.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for MEX:ABBV:
5-Year Yield-on-Cost %: 3.83 (24% below median its 10-year median of 5.01)
GF Value™: MXN3,770.50 vs. price of MXN4,331.99 (14.9% above fair value)
Industry Position: 66.5% above the Drug Manufacturers median (#179 of 514)
No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
72GF Score
Get the complete analysis for MEX:ABBV
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABBV has been successfully added to your 
